Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,281 to 4,300 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| FFR Guided PCI vs CABG: Number of Participants Experiencing Stroke | 7 of 755 8 of 741 | -0.2 points -1.3 to 1.0 | 1,496 | NCT02100722 A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease |
| FFR Guided PCI vs CABG: Number of Participants Experiencing Acute Kidney Injury | 1 of 755 7 of 741 | -0.8 points -1.8 to -0.0 | 1,496 | NCT02100722 A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease |
| D2S Intervention vs Usual Care: Timely Viral Suppression | 309 of 601 352 of 893 | 12.0 points 6.9 to 17.1 | 1,494 | NCT05140421 Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program |
| D2S Intervention vs Usual Care: deaths from any cause | 119 of 601 121 of 893 | 6.3 points 2.4 to 10.2 | 1,494 | NCT05140421 Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program |
| FIRMAGON vs GnRH Agonist: deaths from any cause | 141 of 1,000 72 of 493 | -0.5 points -4.5 to 3.1 | 1,493 | NCT01234350 A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON |
| FIRMAGON vs GnRH Agonist: serious adverse events | 236 of 1,000 144 of 493 | -5.6 points -10.5 to -0.9 | 1,493 | NCT01234350 A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON |
| Varenicline vs Placebo: serious adverse events | 28 of 751 16 of 742 | 1.6 points -0.2 to 3.4 | 1,493 | NCT01370356 A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction |
| Dose-Escalated Radiation Therapy Alone vs Dose-Escalated Radiation Therapy and Short-Term Androgen-Deprivation: deaths from any cause | 119 of 750 100 of 742 | 2.4 points -1.2 to 6.0 | 1,492 | NCT00936390 Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer |
| PLWHIV With COVID-19 Cases vs PLWHIV Without COVID-19 Controls: Chronic Kidney Disease | 38 of 500 32 of 992 | 4.4 points 2.0 to 7.2 | 1,492 | NCT05481216 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV |
| PLWHIV With COVID-19 Cases vs PLWHIV Without COVID-19 Controls: Chronic Obstructive Pulmonary Disease | 36 of 500 43 of 992 | 2.9 points 0.4 to 5.7 | 1,492 | NCT05481216 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV |
| TAC (Docetaxel) vs FAC (5-fluorouracil): Number of Participants With Disease-Free Survival Events | 287 of 745 333 of 746 | -6.1 points -11.1 to -1.1 | 1,491 | NCT00688740 Docetaxel in Node Positive Adjuvant Breast Cancer |
| TAC (Docetaxel) vs FAC (5-fluorouracil): Number of Participants With Overall Survival Events | 188 of 745 241 of 746 | -7.1 points -11.6 to -2.5 | 1,491 | NCT00688740 Docetaxel in Node Positive Adjuvant Breast Cancer |
| TAC (Docetaxel) vs FAC (5-fluorouracil): Number of Participants With Second Primary Malignancies (Toxicity) | 67 of 745 66 of 746 | 0.1 points -2.8 to 3.1 | 1,491 | NCT00688740 Docetaxel in Node Positive Adjuvant Breast Cancer |
| FMX101, 4% Minocycline Foam vs Vehicle Foam: IGA Treatment Success (Dichotomized as Yes/no) at Week 6, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 6 | 84 of 738 46 of 750 | 5.2 points 2.4 to 8.2 | 1,488 | NCT03271021 A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris |
| FMX101, 4% Minocycline Foam vs Vehicle Foam: Investigator Global Assessment (IGA) Treatment Success (Dichotomized as Yes/no) at Week 12, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline | 199 of 738 133 of 750 | 9.2 points 5.0 to 13.4 | 1,488 | NCT03271021 A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris |
| FMX101, 4% Minocycline Foam vs Vehicle Foam: IGA Treatment Success (Dichotomized as Yes/no) at Week 9, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 9 | 137 of 738 79 of 750 | 8.0 points 4.5 to 11.6 | 1,488 | NCT03271021 A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris |
| Task-shifted Epilepsy Care Arm (TSC) vs Enhanced Usual Epilepsy Care Arm (EUC): 75% or Greater Reduction in Seizure Frequency as Determined by the Blinded Physician at 24 Months Follow-up Visit | 636 of 763 531 of 725 | 10.1 points 5.9 to 14.3 | 1,488 | NCT04290975 Bridging the Childhood Epilepsy Treatment Gap in Africa |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Composite of Major and Non-major Bleeding Events | 33 of 988 14 of 499 | 0.5 points -1.5 to 2.3 | 1,487 | NCT01674647 Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion |
| Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Major Bleedings as Per Central Adjudication | 6 of 988 4 of 499 | -0.2 points -1.5 to 0.7 | 1,487 | NCT01674647 Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion |
| Rivaroxaban (Xarelto; BAY59-7939) vs Vitamin K Antagonist: serious adverse events | 93 of 988 38 of 499 | 1.8 points -1.3 to 4.6 | 1,487 | NCT01674647 Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion |
Code
curl "https://conductscience.org/api/comparisons/v1?page=215"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=215
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02100722-07d64fcb",
"title": "FFR Guided PCI vs CABG: Number of Participants Experiencing Stroke",
"summary": "7 of 755 against 8 of 741; risk difference -0.2 points, 95% interval -1.3 to 1.0; NCT02100722, A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease",
"record": "/library/comparisons/NCT02100722-07d64fcb",
"nct_id": "NCT02100722",
"kind": "outcome",
"participants": 1496,
"risk_difference": {
"value": -0.0015246981437291637,
"lower": -0.01293300885823011,
"upper": 0.009572898130875111
},
"group_1": "7 of 755",
"group_2": "8 of 741",
"difference": "-0.2 points",
"interval": "-1.3 to 1.0",
"trial_title": "A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease"
},
{
"id": "NCT02100722-b9e3a38f",
"title": "FFR Guided PCI vs CABG: Number of Participants Experiencing Acute Kidney Injury",
"summary": "1 of 755 against 7 of 741; risk difference -0.8 points, 95% interval -1.8 to -0.0; NCT02100722, A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease",
"record": "/library/comparisons/NCT02100722-b9e3a38f",
"nct_id": "NCT02100722",
"kind": "outcome",
"participants": 1496,
"risk_difference": {
"value": -0.008122190345961695,
"lower": -0.01810525273603738,
"upper": -0.00028984580425778055
},
"group_1": "1 of 755",
"group_2": "7 of 741",
"difference": "-0.8 points",
"interval": "-1.8 to -0.0",
"trial_title": "A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=216",
"request_id": "8b9-n51YO8R9GaSI"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant